Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TuHURA Biosciences Inc (HURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: HURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.08
1 Year Target Price $12.08
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.4% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 96.97M USD | Price to earnings Ratio - | 1Y Target Price 12.08 |
Price to earnings Ratio - | 1Y Target Price 12.08 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 1.80 - 11.83 | Updated Date 06/30/2025 |
52 Weeks Range 1.80 - 11.83 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.68% | Return on Equity (TTM) -332.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 91193774 | Price to Sales(TTM) - |
Enterprise Value 91193774 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 43680400 | Shares Floating 21286767 |
Shares Outstanding 43680400 | Shares Floating 21286767 | ||
Percent Insiders 41.96 | Percent Institutions 8.43 |
Analyst Ratings
Rating 2 | Target Price 12.08 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TuHURA Biosciences Inc
Company Overview
History and Background
TuHURA Biosciences, Inc. (formerly known as Cytokine, Inc.) is a clinical-stage, immunotherapy company focused on developing next generation cancer therapies that utilize the patientu2019s own immune system to eradicate cancer cells. It was founded with the aim of developing novel cancer immunotherapies. The company's focus has shifted over time to developing and commercializing personalized cancer treatments.
Core Business Areas
- Oncolytic Virus Therapy: TuHURA Biosciences is developing tumor-selective, engineered viruses to selectively infect and destroy cancer cells while stimulating an immune response against the tumor.
- Personalized Immunotherapy: TuHURA focuses on therapies tailored to an individual patient's tumor and immune profile to maximize treatment efficacy.
Leadership and Structure
The leadership team consists of experienced professionals in the biotechnology and pharmaceutical industries. The organizational structure is typically composed of research and development, clinical operations, and commercial strategy departments. Specific leadership details fluctuate and should be verified with current sources.
Top Products and Market Share
Key Offerings
- TAK-605: Oncolytic virus therapy currently in clinical trials for various solid tumors. Market share is currently 0% as it's not yet approved. Competitors include companies developing other oncolytic virus therapies and immunotherapies, such as Amgen (T-VEC), Replimune, and BioNTech/Pfizer.
- Personalized neoantigen therapy: TuHURA is developing cancer therapies based on tumor specific neoantigens to stimulate the patient's immune system. Market share is currently 0% as it is in the early stages. Competitors include BioNTech/Pfizer, Moderna, Gritstone Bio.
Market Dynamics
Industry Overview
The cancer immunotherapy market is experiencing significant growth, driven by advancements in understanding the immune system's role in cancer and the development of novel therapeutic approaches. It is a competitive landscape with many players.
Positioning
TuHURA Biosciences is positioning itself as a leader in personalized cancer immunotherapy, focusing on developing innovative therapies that harness the power of the patient's immune system. They are currently in the development stage.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. TuHURA Biosciences aims to capture a portion of this market through its personalized immunotherapy platforms.
Upturn SWOT Analysis
Strengths
- Proprietary oncolytic virus platform.
- Focus on personalized immunotherapy.
- Experienced management team.
- Novel approach to cancer treatment.
Weaknesses
- Limited financial resources.
- Early stage of development.
- Reliance on clinical trial success.
- Lack of commercialized products.
Opportunities
- Partnerships with larger pharmaceutical companies.
- Expansion into new cancer indications.
- Advancements in immunotherapy technologies.
- Increasing demand for personalized cancer treatments.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles.
- Clinical trial failures.
- Changes in reimbursement policies.
Competitors and Market Share
Key Competitors
- AMGN
- MRNA
- BNTX
- GRTS
Competitive Landscape
TuHURA Biosciences faces competition from established pharmaceutical companies with greater resources and more advanced product pipelines. However, its personalized immunotherapy approach could differentiate it in the market.
Growth Trajectory and Initiatives
Historical Growth: TuHURA Biosciences is in the early stages of growth, with its growth trajectory heavily dependent on the success of its clinical trials and partnerships.
Future Projections: Future growth projections are based on analyst estimates and are subject to significant uncertainty. Analyst forecasts would need to be gathered from available sources.
Recent Initiatives: Recent initiatives include advancing clinical trials of its lead product candidates and exploring potential partnerships with pharmaceutical companies.
Summary
TuHURA Biosciences is a development-stage company focused on innovative cancer immunotherapies. The company's strength lies in its personalized approach to cancer treatment and the potential of its oncolytic virus platform. However, it faces challenges related to limited resources, clinical trial risks, and intense competition. The company needs to secure partnerships and successfully advance its clinical programs to realize its growth potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available information and subject to change. All investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TuHURA Biosciences Inc
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2013-02-22 | President, CEO & Director Dr. James A. Bianco M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.tuhurabio.com |
Full time employees 19 | Website https://www.tuhurabio.com | ||
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.